PhD Scientific Days 2023

Budapest, 22-23 June 2023

Clinical Medicine V.

Outcomes of high-risk adult outpatients with haematological malignancies treated with early remdesivir therapy during the SARS-CoV-2 omicron era: a single-centre prospective cohort study from the national centre of Hungary

Zsófia GÁSPÁR MD1,2, Bálint Gergely SZABÓ MD PhD1,2,3, Anita ÁBRAHÁM MD1, Zsuzsanna VÁRNAI MD1, Noémi KISS-DALA MD PhD1,2, János SZLÁVIK MD1, János SINKÓ MD PhD1,3, István VÁLYI-NAGY MD PhD1, Botond LAKATOS MD PhD1,2,3
1 South Pest Central Hospital, National Institute of Haematology and Infectious Diseases, (Albert Flórián Street 5-7., H-1097, Budapest, Hungary)
2 School of PhD Studies, Semmelweis University (Üllői Street 26., H-1085, Budapest, Hungary)
3 Departmental Group of Infectious Diseases, Department of Internal Medicine and Haematology, Semmelweis University (Albert Flórián Street 5-7., H-1097, Budapest, Hungary)

Text of the abstract

Introduction: Emerging evidence suggests that remdesivir might improve clinical outcomes of high-risk outpatients with COVID-19.
Aims: Our aim was to evaluate the characteristics and outcomes of non-hospitalized adults with haematological malignancies diagnosed with COVID-19 and treated with early remdesivir therapy during the omicron wave.
Method: A single-centre prospective cohort study was performed among adult patients between February–June 2022, during the circulation of PANGO subvariants BA.2, BA.4 and BA.5 in Hungary. Patients were enrolled based on predefined criteria. Clinical characteristics (demography, comorbidities, vaccination status, imaging, treatment, and disease course) and outcomes (COVID-19-related hospitalisation, oxygen supplementation, intensive care support, all-cause death) were assessed at 28-days post-treatment.
Results: Altogether 127 patients were enrolled: 51.2% (65/127) were female with a median age of 59±22 (21‒92) years, and 48.8% (62/127) had active haematological malignancy. At 28-days post-treatment, 7.1% (9/127) of patients required COVID-19-related hospitalisation, 2,4% (3/127) required oxygen supplementation, 1,6% (2/127) required intensive care, and 0.8% (1/127) died due to a non-COVID-19 related secondary bacterial infection at the intensive care unit, all with haematological malignancies.
Conclusion: Early remdesivir treatment might be a feasible strategy among high-risk outpatients with haematological malignancies and COVID-19 during the omicron wave.
Funding: The article did not receive any external funding.